Blast-enriched suspensions of T cells primed for Chlamydia trachomatis antigen were cloned by a limiting dilution technique. A cloning efficiency of 20-25% was obtained. T-lymphocyte clones (TLC) with high proliferative responses were selected for further studies. Kinetic studies showed a peak response between 60 and 84 h after antigen stimulation. The TLC were OKT4+. They were specific for the chlamydial antigen and did not respond to other antigens when non-T cells were used as antigen-presenting cells (APC). Antigen-specific proliferation of the TLC required that the responding TLC and the APC shared class-II HLA determinants--that is, HLA-D/DR molecules. The true clonal nature of the TLC was confirmed by subcloning experiments.

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1365-3083.1983.tb01800.xDOI Listing

Publication Analysis

Top Keywords

t-lymphocyte clones
8
chlamydia trachomatis
8
tlc
5
antigen-specific proliferative
4
proliferative human
4
human t-lymphocyte
4
clones specificity
4
specificity chlamydia
4
trachomatis blast-enriched
4
blast-enriched suspensions
4

Similar Publications

Background: Triple-negative breast cancer (TNBC) is among the most aggressive forms of breast cancer, characterized by a dismal prognosis. In the absence of drug-targetable receptors, chemotherapy remains the sole systemic treatment alternative. Recent advancements in immunotherapy, particularly immune checkpoint inhibitors (ICIs) that target programmed death 1/programmed death ligand 1 (PD-1/PD-L1) and cytotoxic T lymphocyte associated antigen 4 (CTLA-4), have provided renewed optimism for the treatment of patients with TNBC.

View Article and Find Full Text PDF

Liver cancer is the sixth most frequent malignancy and the fourth major cause of deaths worldwide. The current treatments are only effective in early stages of cancer. To overcome the therapeutic challenges and exploration of immunotherapeutic options, broad spectral therapeutic vaccines could have significant impact.

View Article and Find Full Text PDF

Background: Mature T-cell neoplasms arise from the neoplastic transformation of a single T lymphocyte, and all cells in a neoplastic clone share the same V segment in the beta chain of the T-cell receptor (TCR). These segments may represent an innovative target for the development of targeted therapies.

Methods: A specific V segment of the TCR beta chain (TRBV5-1) was analyzed using bioinformatic tools, identifying three potential antigenic peptides.

View Article and Find Full Text PDF

Bovine viral diarrhea virus (BVDV) is a significant pathogen that exerts substantial economic influence on the global cattle industry. Developing a safe and effective novel vaccine targeting various BVDV subtypes is critical for controlling BVDV infection. In the study, we created two distinct multi-epitope vaccines by linking highly conserved and dominant cytotoxic T-lymphocytes (CTL), helper T-lymphocytes (HTL), and B-cell epitopes from either the E0 or E2 envelope glycoprotein of diverse BVDV subtypes.

View Article and Find Full Text PDF

Regulatory T cells (Tregs) contribute significantly to the immunosuppressive nature of the tumor microenvironment which is a main barrier for immunotherapies of solid cancers. Reducing Treg numbers enhances anti-tumor immune responses but current depletion strategies also impair effector T cells (Teffs), potentially leading to reduced anti-tumor immunity and/or autoimmune diseases. CD137 has been identified as the most differentially expressed gene between peripheral Tregs and intratumoral Tregs in virtually all solid cancers.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!